Journal article
A multicenter, randomized, controlled study to investigate extending the time for thrombolysis in emergency neurological deficits with intra-arterial therapy (EXTEND-IA)
BCV Campbell, PJ Mitchell, B Yan, MW Parsons, S Christensen, L Churilov, RJ Dowling, H Dewey, M Brooks, F Miteff, C Levi, M Krause, TJ Harrington, KC Faulder, BS Steinfort, T Kleinig, R Scroop, S Chryssidis, A Barber, A Hope Show all
International Journal of Stroke | WILEY-BLACKWELL | Published : 2014
DOI: 10.1111/ijs.12206
Abstract
Background and Hypothesis: Thrombolysis with tissue plasminogen activator is proven to reduce disability when given within 4·5h of ischemic stroke onset. However, tissue plasminogen activator only succeeds in recanalizing large vessel arterial occlusion in a minority of patients. We hypothesized that anterior circulation ischemic stroke patients, selected with 'dual target' vessel occlusion and evidence of salvageable brain using computed tomography or magnetic resonance imaging 'mismatch' within 4·5h of onset, would have improved reperfusion and early neurological improvement when treated with intra-arterial clot retrieval after intravenous tissue plasminogen activator compared with intrave..
View full abstractGrants
Funding Acknowledgements
The study is managed by the steering committee and executive sub-committees and financially supported by the National Health and Medical Research Council (NHMRC) of Australia, National Heart Foundation of Australia (NHF), National Stroke Foundation of Australia (NSF), a Royal Melbourne Hospital Home Lottery Project Grant, and the Royal Australasian College of Physicians (RACP). In kind logistic support is provided by the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Neuroscience Trials Australia, the Melbourne Brain Centre at the Royal Melbourne Hospital, and the Florey Institute of Neuroscience and Mental Health. Covidien (manufacturer of the Solitaire FR device) will provide the study device free of charge and additional infrastructure funding but have no role in the design or analysis of the study. The sponsor of the study is the National Stroke Research Institute (NSRI), a division of the Florey Institute of Neuroscience and Mental Health.